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ABSTRACT
Objectives To investigate the role of liver X receptors
(LXRs) in experimental skin ﬁbrosis and evaluate their
potential as novel antiﬁbrotic targets.
Methods We studied the role of LXRs in bleomycin-
induced skin ﬁbrosis, in the model of sclerodermatous
graft-versus-host disease (sclGvHD) and in tight skin-1
(Tsk-1) mice, reﬂecting different subtypes of ﬁbrotic
disease. We examined both LXR isoforms using LXRα-,
LXRβ- and LXR-α/β-double-knockout mice. Finally, we
investigated the effects of LXRs on ﬁbroblasts and
macrophages to establish the antiﬁbrotic mode of action
of LXRs.
Results LXR activation by the agonist T0901317 had
antiﬁbrotic effects in bleomycin-induced skin ﬁbrosis, in
the sclGvHD model and in Tsk-1 mice. The antiﬁbrotic
activity of LXRs was particularly prominent in the
inﬂammation-driven bleomycin and sclGvHD models.
LXRα-, LXRβ- and LXRα/β-double-knockout mice
showed a similar response to bleomycin as wildtype
animals. Low levels of the LXR target gene ABCA-1 in
the skin of bleomycin-challenged and control mice
suggested a low baseline activation of the antiﬁbrotic
LXR signalling, which, however, could be speciﬁcally
activated by T0901317. Fibroblasts were not the direct
target cells of LXRs agonists, but LXR activation
inhibited ﬁbrosis by interfering with inﬁltration of
macrophages and their release of the pro-ﬁbrotic
interleukin-6.
Conclusions We identiﬁed LXRs as novel targets for
antiﬁbrotic therapies, a yet unknown aspect of these
nuclear receptors. Our data suggest that LXR activation
might be particularly effective in patients with
inﬂammatory disease subtypes. Activation of LXRs
interfered with the release of interleukin-6 from
macrophages and, thus, inhibited ﬁbroblast activation
and collagen release.
INTRODUCTION
Fibrosis arises from excessive accumulation of
extracellular matrix, disrupts the physiological
tissue architecture and causes organ failure. Fibrotic
diseases lead to high morbidity and mortality
among patients, and represent a major socio-
economic burden accounting for up to 45% of
deaths in the developed world. Despite the urgent
medical need, effective antiﬁbrotic therapies are
not available for clinical routine.1 2
Fibrosis is a pathological hallmark of systemic
sclerosis (SSc). In SSc, ﬁbrosis affects the skin and
many internal organs, including the lungs, heart
and gastrointestinal tract.3 4 Inﬂammatory cell inﬁl-
trates with macrophages, T cells and B cells are a
common feature in affected tissues of SSc and
other ﬁbrotic diseases. The inﬁltrating leucocytes
release pro-ﬁbrotic cytokines, including interleukin
(IL)-6. The pro-ﬁbrotic signals induce the activation
of ﬁbroblasts, which in turn express contractile pro-
teins, form stress ﬁbres and release extracellular
matrix proteins (eg, collagens).1 3 4
The activation of ﬁbroblasts can be observed
during both normal wound healing and patho-
logical ﬁbrosis. During normal wound responses,
the activation of ﬁbroblasts is strictly terminated
once wound healing is completed. During patho-
logical ﬁbrosis, however, persistent release of pro-
ﬁbrotic signals from inﬂammatory cells as well as
endogenous ﬁbroblast modiﬁcations (eg, epigenetic
codes, autocrine signalling loops) result in chronic
ﬁbroblast activation with excessive release of extra-
cellular matrix proteins.1 3 4 Although the exact
molecular mechanisms of chronic ﬁbroblast activa-
tion are only partially revealed, interference with
these processes is considered a promising treatment
approach for SSc and other ﬁbrotic diseases.1 2
Liver X receptors (LXRs) are nuclear receptors
with emerging roles in metabolic and musculoskel-
etal disorders,5–8 autoimmune diseases9–17 and neo-
plasia.18 Based on highly conserved homologies of
the nuclear receptor family, LXRs were ﬁrst identi-
ﬁed by their cloned sequences prior to the identiﬁca-
tion of natural ligands and even prior to the
discovery of any functional role. Research over the
last 15 years has identiﬁed oxysterols and related
metabolites of the cholesterol metabolism as poten-
tial natural ligands of LXRs, although it remains
unclear whether physiological concentrations are
able to bind to and activate these receptors. Apart
from the identiﬁcation of potential ligands, further
studies demonstrated central roles of LXRs in chol-
esterol and glucose metabolism as well as in tumour
surveillance and inﬂammatory responses.19 20
In the present study, we evaluated LXRs as
potential therapeutic targets in ﬁbrotic disease, in
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particular SSc. We observed that activation of LXRs had antiﬁ-
brotic effects in the models of bleomycin-induced skin ﬁbrosis
and in tight skin-1 (Tsk-1) mice. The antiﬁbrotic effects of
LXRs were mediated via inhibition of IL-6 release from
macrophages.
MATERIALS AND METHODS
Mice and therapeutics
Mouse experiments and the analyses of murine skin are
described in the online supplement. T0901317 was obtained
from Sigma-Aldrich (Taufkirchen, Germany). The anti-IL-6 anti-
body 20F3 was provided by Professor S. Rose-John.21 All
animal experiments were performed with the approval of the
local ethics authorities.
Murine macrophage experiments
Macrophages were isolated from peritonitis exudates of naive
10-week to 12-week-old FVB mice, 72 h after intraperitoneal
injection of 2.5 mL of 3% Brewer’s thioglycollate
(Sigma-Aldrich). Peritoneal macrophages were harvested by peri-
toneal lavage with ice-cold 4% fetal bovine serum (FBS) in
phosphate buffered saline (PBS) and plated in 48-well plates in a
concentration of 1 Mio/mL (250 000 cells per well).
Macrophages were allowed to rest overnight at 37°C at 5% CO2
in Roswell Park Memorial Institute (RPMI) medium supplemen-
ted with 10% FBS before starting experiments. FBS concentra-
tion was then reduced to 0.5% for 24 h. After macrophages
were preincubated with T0901317 in a concentration of 5 mM
for 3 h, they were stimulated with lipopolysaccharide (LPS)
100 ng/mL (Sigma-Aldrich, Taufkirchen, Germany) for up to
24 h. T0901317 was dissolved in dimethyl sulfoxide (DMSO);
the ﬁnal concentration of DMSO in the experiments did not
exceed 0.1%.
Human ﬁbroblast experiments
Fibroblast cultures were obtained from skin biopsies of six SSc
patients. All SSc patients presented with diffuse-cutaneous SSc,
and 3 mm punches were taken from lesional skin at the volar
side of the forearm. Fibroblast isolation and culture were per-
formed as described previously.22–24 All SSc patients provided
written informed consent as approved by the institutional ethics
committees.
Fibroblasts from passages 4 to 8 were used for the experi-
ments. Fibroblasts were seeded in 6-well plates and grown in
Dulbecco’s modiﬁed Eagle’s medium (DMEM) supplemented
with 10% FBS until cells reached conﬂuence. FBS was reduced
to 0.1% for 48 h. Fibroblasts were pretreated with T0901317 in
a concentration of 5.0 mM for 3 h and then stimulated with
recombinant transforming growth factor-β (TGF-β) (10 ng/mL;
R&D Systems, Abingdon, UK). Forty-eight hours after TGF-β
stimulation, supernatants were collected (to measure collagen
content) and cells lysed in RAI buffer (for RNA analysis;
NucleoSpin RNA II extraction system). T0901317 was dissolved
in DMSO; the ﬁnal concentration of DMSO in the experiments
did not exceed 0.1%.
Human macrophage experiments
Peripheral blood mononuclear cells (PBMCs) were isolated from
the peripheral blood of ﬁve SSc patients using Lymphoﬂot®
(Bio-Rad, Hercules, California, USA) according to the manufac-
turer’s recommendations. All SSc patients provided written
informed consent as approved by the institutional ethics com-
mittees. PBMCs were seeded in RPMI supplemented with 0.5%
FBS in a concentration of 1×106/mL. Monocytic cells were
allowed to adhere to the plastic ground for 2 h at 37°C, and
non-adherent cells were washed away with warm PBS.
Afterwards, monocytes were kept in RPMI with 10% FBS and
10% autologous serum for 7 days to allow the differentiation
into macrophages. At day 8, the medium was replaced by fresh
RPMI with 0.5% FBS. Twenty-four hours later, studies were
performed according to the murine macrophage experiments.
IL-6 ELISA
IL-6 was determined in the supernatants from the murine
macrophage experiments with the mouse IL-6 DuoSet ELISA
(R&D Systems, Minneapolis, Minnesota, USA).
Multiplex bead array
Cytokine levels were measured in the supernatants from the
human macrophage experiments by multiplex bead array tech-
nology (Bender MedSystems, Vienna, Austria) as described
previously.25 26
Quantitative real-time PCR (qPCR)
Gene expression was quantiﬁed by SYBR green real-time PCR
on a Stratagene Mx3005 qPCR System (Agilent Technologies,
Santa Clara, California, USA). Nonspeciﬁc signals caused by
primer dimers were excluded by dissociation curve analysis and
use of non-template controls. To normalise for loaded cDNA,
β-actin was used as an endogenous control.
Statistical analysis
All data are presented as median with IQR. Differences between
the groups were tested for their statistical signiﬁcance by two-
tailed Mann–Whitney U non-parametric test using GraphPad
Prism (V.5.03) except indicated otherwise. p values less than
0.05 were considered signiﬁcant.
RESULTS
Activation of LXRs inhibits bleomycin-induced skin ﬁbrosis
To investigate the role of LXRs in experimental ﬁbrosis, we
studied the effects of the LXR agonist T0901317 in the model of
bleomycin-induced skin ﬁbrosis. When we treated
bleomycin-challenged mice with T0901317, we observed potent,
dose-dependent antiﬁbrotic effects on skin thickening, hydroxy-
proline content and myoﬁbroblast numbers (ﬁgure 1A–D). In the
group of mice receiving T0901317 in a dose of 25 mg/kg once
daily, we found a decrease in skin thickening of 64.1% (CI
21.6% to 114.2%), a reduction in the hydroxyproline content of
90.7% (CI 14.9% to 275.1%) and a decrease in myoﬁbroblast
counts by 91.3% (CI 51.4% to 139.0%) (ﬁgure 1B–D). Apart
from the potent antiﬁbrotic effects of LXR activation, we
observed a strong decline in inﬂammatory inﬁltrates by 60.2%
(CI 11.9% to 154.6%) in the group of mice receiving 25 mg/kg/d
T0901317 (ﬁgure 1E). The potent antiﬁbrotic and anti-
inﬂammatory effects of LXR activation were accompanied by
excellent tolerability: throughout all bleomycin experiments,
mice tolerated both doses of T0901317 well as indicated by
constant weight, normal texture of the fur and normal activity
(data not shown).
LXR activation inhibits ﬁbrosis in the model of
sclerodermatous GvHD (sclGvHD)
Given the extent of skin ﬁbrosis and the substantial overlap in
gene expression proﬁles, murine sclGvHD is considered an
elegant model to study inﬂammatory, diffuse-cutaneous
SSc.27 28 By contrast to their syngenic controls, mice receiving
allogenic bone marrow transplantation developed clinical signs,
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including hair loss and superﬁcial skin ulcerations, as well as
severe skin ﬁbrosis (ﬁgure 2A–E). Treatment with the LXR
agonist T0901317 was started on day 21 after transplantation
when ﬁrst clinical signs became obvious, and it was continued
to day 42 when mice were sacriﬁced. We observed that LXR
activation reduced weight loss, improved clinical signs (data not
Figure 1 Activation of liver X receptors by T0901317 inhibits the development of bleomycin-induced skin ﬁbrosis in a dose-dependent manner. (A)
Representative images of Masson’s trichrome staining with blue staining for collagens. Mice were challenged with bleomycin subcutaneously and
received daily per os feeding with T0901317 in different doses. Pictures are shown at 100-fold magniﬁcation. Scale bar, 100 mm. (B) Skin thickening
as determined in trichrome stainings. (C) Hydroxyproline (HP) content. (D) α-smooth muscle actin-positive myoﬁbroblasts. (E) Inﬂammatory inﬁltrates
as determined in H&E stainings. The groups consisted of ≥6 mice each.
Figure 2 Activation of liver X receptors by T0901317 inhibits the development of systemic ﬁbrosis in sclerodermatous graft-versus-host disease
(sclGvHD). (A) Representative images of Masson’s trichrome staining with blue staining for collagens. Mice were subject to allogenic stem cell
transplantation and received daily per os feeding with T0901317 from day 21 to 42 after transplantation. Pictures are shown at 100-fold
magniﬁcation. Scale bar, 100 mm. (B) Skin thickening as determined in trichrome stainings. (C) Hydroxyproline (HP) content. (D) α-smooth muscle
actin-positive myoﬁbroblasts. (E) Inﬂammatory inﬁltrates as determined by H&E stainings. The syngenic group consisted of four mice, the two other
groups of six mice each.
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shown) and inhibited skin ﬁbrosis in mice receiving allogenic
stem cell transplantation (ﬁgure 2B–E). In detail, treatment with
the LXR agonist T0901317 reduced skin thickening by 69.4%
(CI 15.3% to 143.1%), hydroxyproline content by 122.6% (CI
19.6% to 458.3%), myoﬁbroblast counts by 89.9% (CI 32.6%
to 306.9%) and leucocyte inﬁltration by 60.5% (CI 40.4% to
206.2%). Together with the data from the bleomycin model,
these results highlight that LXR activation effectively inhibits
inﬂammation-driven ﬁbrosis induced by both exogenous, pro-
ﬁbrotic toxins and intrinsic autoimmune processes.
LXRs activation is not required to maintain skin homeostasis
Next, we analysed whether knockout of LXR might exacerbate
bleomycin-induced skin ﬁbrosis. Both LXRα-knockout and
LXRβ-knockout mice showed similar responses to bleomycin as
wildtype mice with comparable increases in skin thickening,
hydroxyproline content and myoﬁbroblast counts (see online
supplementary ﬁgure S1A–F). To exclude that lack of one
isoform could be compensated by the other one, we generated
LXRα/β-double-knockout mice. Similar to the single knockout
animals, the double knockout mice showed a comparable
response to the bleomycin challenge as wildtype animals
(ﬁgure 3A–E). Since we observed low expression levels of the
LXR target gene ABCA-1 in both NaCl- and bleomycin-
challenged wildtype mice, we concluded that LXR signalling
may be characterised by low baseline activation in skin tissue
(ﬁgure 5C). Treatment with T0901317, however, resulted in a
strong increase in expression of ABCA-1 demonstrating the high
responsiveness of ﬁbrotic skin towards LXR agonists (ﬁgure
5C). While low baseline activity suggested the dispensability of
LXRs for normal tissue homeostasis of the skin, speciﬁc LXR
activation was effective in stimulating an antiﬁbrotic signalling
cascade and inhibiting skin ﬁbrosis.
Taking advantage of LXRα/β-double knockout mice, we con-
ﬁrmed that the antiﬁbrotic effects of T0901317 in
bleomycin-induced dermal ﬁbrosis were indeed mediated via
LXRs and not caused by off-target effects of T0901317. In con-
trast to wildtype mice, treatment with T0901317 was ineffective
to reduce skin thickening, hydroxyproline content, α-smooth
muscle actin-positive myoﬁbroblasts or leucocyte counts in
LXRα/β-double knockout mice challenged with bleomycin
(ﬁgure 3A–E).
Activation of LXRs inhibits skin ﬁbrosis in the Tsk-1 mouse
model
Bleomycin-induced skin ﬁbrosis and sclGvHD both reﬂect
inﬂammatory subtypes of SSc. To also mimic other subsets of
SSc patients with less pronounced inﬂammation, we investigated
the antiﬁbrotic effects of LXRs in the Tsk-1 mouse model.
Although Tsk-1 mice show B cell activation and develop auto-
antibodies against SSc-antigens, inﬂammatory inﬁltrates are
absent or scarce in this model.28 In Tsk-1 mice, activation of
LXRs with T0901317 had only modest antiﬁbrotic effects
(ﬁgure 4A–D). Although statistically signiﬁcant, reductions of
skin thickening, hydroxyproline content and myoﬁbroblast
counts were far less prominent as observed in the inﬂammatory
models of bleomycin-induced skin ﬁbrosis and sclGvHD.
Activation of LXRs reduces the release of the pro-ﬁbrotic
IL-6 from macrophages
The prominent antiﬁbrotic activity of LXRs in the inﬂammatory
bleomycin-model exceeded the effects we observed in the Tsk-1
mouse model. Based on these observations, we considered an
indirect, leucocyte-dependent mechanism for the antiﬁbrotic
effects of LXR agonists. To test this hypothesis, we ﬁrst analysed
the direct effects of T0901317 on cultured human ﬁbroblasts.
Although we found that both isoforms, LXRα and LXRβ, were
expressed in healthy and SSc skin as well as ﬁbroblasts isolated
from healthy and SSc skin (data not shown), treatment with
T0901317 in different concentrations did not alter the release
of collagens from resting ﬁbroblasts or ﬁbroblasts stimulated
with pro-ﬁbrotic cytokines, such as TGF-β (ﬁgure 5A,B).
Figure 3 LXRα/β-double-knockout mice do not show exacerbation of bleomycin-induced skin ﬁbrosis. (A) Representative images of Masson’s
trichrome staining with blue staining for collagens. LXRα/β-double-knockout mice were challenged with bleomycin subcutaneously and received
daily per os feeding with T0901317 in a dose of 25 mg/kg. Pictures are shown at 100-fold magniﬁcation. Scale bar, 100 mm. (B) Skin thickening as
determined by trichrome staining. (C) Hydroxyproline (HP) content. (D) α-SMA positive myoﬁbroblasts. (E) Inﬂammatory inﬁltrates as determined in
H&E stainings. The groups consisted of ≥6 mice each. LXRα, liver X receptor α.
4 Beyer C, et al. Ann Rheum Dis 2014;0:1–8. doi:10.1136/annrheumdis-2013-204401
Basic and translational research
 group.bmj.com on April 1, 2014 - Published by ard.bmj.comDownloaded from 
To investigate the role of leucocytes, we then studied the
inﬂammatory inﬁltrates in bleomycin-challenged mice and
observed a pronounced reduction of inﬁltrating macrophages
upon treatment with T0901317, with decreases of 70.9% (CI
26.4% to 135.0%) for the dose of 25 mg/kg/day (ﬁgure 5D).
We wondered whether LXR activation may not only reduce the
number of macrophages in lesional tissue but also interfere with
the release of pro-ﬁbrotic mediators from these cells. Indeed, we
observed that LXR activation signiﬁcantly inhibited the synthesis
and release of IL-6 from isolated macrophages upon stimulation
with LPS (ﬁgure 5F,G). Twenty-four hours after stimulation,
IL-6 protein was reduced by 72.0% (CI 30.0% to 135.2%)
(ﬁgure 5G). Translating these ﬁndings in our in vivo model
system, we observed decreased IL-6 levels in
bleomycin-challenged mice treated with the LXR agonist
T0901317 (ﬁgure 5E, see online supplementary ﬁgure S2).
Of note, LXR agonists did not exert additive antiﬁbrotic
effects in bleomycin-challenged mice treated with anti-IL-6
blocking antibodies. Co-treatment with anti-IL-6 antibodies and
T0901317 did not further reduce skin thickness, hydroxypro-
line content and myoﬁbroblast counts as compared with treat-
ment with anti-IL-6 antibodies alone (ﬁgure 5H–J). These
observations suggested that the antiﬁbrotic effects of LXR acti-
vation may indeed be mainly mediated by inhibition of IL-6
release.
Finally, we conﬁrmed our proposed mode of action in the
human system. We isolated monocytic cells from patients with
diffuse-cutaneous SSc, trans-differentiated them into macrophages
and stimulated them with LPS. In line with our results on murine
macrophages, LXR activation signiﬁcantly reduced IL-6 mRNA
levels in macrophages as well as the release of IL-6 protein (see
online supplementary ﬁgure S3A,B). Of note, LXR activation did
not alter IL-4 release from macrophages (see online supplementary
ﬁgure S3D) but showed moderate effects on tumour necrosis
factor (TNF)-α secretion (see online supplementary ﬁgure S3C),
suggesting that blockade of IL-6 in macrophages may be the major
but not exclusive mode of action of LXRs in ﬁbrosis.
DISCUSSION
We identiﬁed the nuclear receptors LXRs as novel therapeutic
targets for SSc and other ﬁbrotic diseases. We demonstrated that
activation of LXRs has potent antiﬁbrotic effects in different
experimental models of ﬁbrosis. These antiﬁbrotic effects are
mediated by suppression of macrophage inﬁltration and
decreased release of the pro-ﬁbrotic cytokine IL-6.
Our ﬁndings open up a new vein of potential applications for
LXRs. So far, research has focused on the roles of LXRs in
metabolic and autoimmune diseases, including diabetes, hyper-
cholesterolaemia, multiple sclerosis and rheumatoid arth-
ritis.14 19 20 In rheumatoid arthritis, the role of LXRs is
controversial. While some research groups suggested that LXRs
could promote disease progression by inducing Th1 and Th17
cytokines, including TNF-α and IL-1β,9–11 others found anti-
inﬂammatory and disease-modifying activities of LXRs in
experimental models of arthritis.12 13 16 17 In the context of
ﬁbrotic disease, we observed that activation of LXRs ameliorates
Figure 4 Activation of liver X receptors inhibits spontaneous skin ﬁbrosis in Tsk-1 mice. (A) Representative images of Masson’s trichrome staining
with blue staining for collagens. Tsk-1 mice received daily per os feeding with T0901317 in a dose of 25 mg/kg. pa/pa mice were used as controls.
Pictures are shown at 40-fold magniﬁcation. Scale bar, 250 mm. (B) Hypodermal thickening as determined by trichrome staining. (C) Hydroxyproline
(HP) content. (D) α-smooth muscle actin-positive myoﬁbroblasts. The groups consisted of ≥6 mice each. Tsk-1, tight skin-1
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inﬂammation and ﬁbrosis, mainly via interfering with the IL-6
release from macrophages.
LXRs are master regulators of glucose and cholesterol homeo-
stasis. Activation of LXRs decreases glucose output and
increases glucose use by inducing the expression of glucose
transporters and enzymes of glycolysis.14 19 20 In addition to
ﬁne tuning glucose metabolism, LXR activation reduced
streptozotocin-induced diabetic retinopathy29 and nephropa-
thy.30 LXRs regulate whole-body cholesterol levels, enhance
reverse cholesterol transport and stimulate cholesterol secretion.
Within the liver, LXRs protect hepatocytes from cholesterol and
bile acid toxicity.31 LXRs may also inhibit hepatic stellate cell
activation upon injury and prevent subsequent ﬁbrotic
responses. In this context, loss of LXRα and LXRβ enhanced
the activation of hepatic stellate cells and exacerbated
CCl4-induced liver injury and ﬁbrosis, while pharmacological
activation of LXRs reduced hepatic stellate cell activation.32
Although these results conﬁrm our ﬁndings on the antiﬁbrotic
role of LXRs, the modes of action of LXRs differ between
experimental ﬁbrosis in liver and skin. While LXRs may directly
inhibit hepatic stellate cell activation and collagen release in
liver ﬁbrosis, we established an indirect antiﬁbrotic mechanism
of LXRs involving the IL-6 release from ﬁbroblasts. The unique
role of hepatic stellate cells in liver ﬁbrosis compared with other
ﬁbrotic diseases in which ﬁbroblasts are the key effector cells
may explain the differences to our ﬁndings in skin ﬁbrosis.
In our study, LXR activation was effective in inhibiting
experimental ﬁbrosis with the most prominent effects in the
inﬂammatory models of bleomycin-induced dermal ﬁbrosis and
sclGvHD. LXR activation reduced inﬂammatory inﬁltrates and
ﬁbrotic changes in inﬂammation-driven experimental skin ﬁbro-
sis by reducing the release of IL-6 from macrophages.
Macrophages are key players in physiologic wound healing and
pathological tissue ﬁbrosis and have been identiﬁed as cellular
Figure 5 The antiﬁbrotic effects of liver X receptor (LXR) activation are mediated via inhibition of macrophage inﬁltration and interleukin (IL)-6
release. (A) Messenger RNA expression of col1a1 pro-collagen in normal ﬁbroblasts from healthy individuals stimulated with TGF-β 10 ng/mL and
pretreated with T0901317 5 mM. Values are expressed as x-folds compared with the control group without TGF-β and T0901317 treatment. N=6 for
each group. (B) Collagen content in the supernatant released from normal ﬁbroblasts of healthy individuals stimulated with TGF-β 10 ng/mL and
pretreated with T0901317 5 mM. N=6 for each group. (C) Messenger RNA expression of the target gene ABCA-1 in mice challenged with bleomycin
and treated with T0901317 25 mg/kg per os once daily. N=6 per group. Values are expressed as x-folds compared with the control group receiving
subcutaneously. NaCl challenge and oral mock treatment. (D) Numbers of F4/80 positive macrophages per high power ﬁeld in the skin of mice
challenged with bleomycin and treated with T0901317 in a dose of 25 mg/kg once daily. N=6 per group. (E) Interleukin-6 staining as assessed by a
semiquantitative score in the skin of mice challenged with bleomycin and treated with T0901317 in a dose of 25 mg/kg once daily. N=6 per group.
(F) Messenger RNA expression of IL-6 from peritoneal macrophages after pretreatment with T0901317 5 mM and stimulation with LPS 100 ng/mL
expressed as x-fold of the untreated and unstimulated control. N=5 for each group. (G) Interleukin-6 release from peritoneal macrophages after
pretreatment with T0901317 5 mM and stimulation with LPS 100 ng/mL. N=5 for each group. (H–J) LXR activation by T0901317 does not have
additive effects in the bleomycin-challenged mice after IL-6 blockade with a monoclonal IL-6 blocking antibody. The groups consisted of ≥6 mice
each. (H) Skin thickening as determined in trichrome stainings. (I) Hydroxyproline (HP) content. ( J) α-smooth muscle actin-positive myoﬁbroblasts.
TGF-β, transforming growth factor-β; LPS, lipopolysaccharide
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key effectors in SSc.33–37 The numbers of monocytes and
macrophages are highly elevated in the affected skin of patients
with early SSc, exceeding those of other cell populations, such
as T cells.38 In later disease stages, there is good evidence for
abnormal differentiation of peripheral mononuclear cells into
activated CD163+ or CD204+ macrophages, which reside
between the collagen ﬁbres.39 While the role of macrophages as
a major source of pro-ﬁbrotic mediators in SSc skin has been
well established,37 evidence for a central role of IL-6 in SSc is
still emerging.40 Three recent studies reported increased serum
levels of IL-6 in SSc, which may correlate with more severe skin
disease, cardiac involvement, progression of lung ﬁbrosis and
overall long-term survival.41–43 These observations have transla-
tional implications for the potential use of LXR agonists in SSc:
based on the mode of action, LXR activation might serve as
effective personalised therapies for SSc patients in early inﬂam-
matory stages or with inﬂammatory disease subtypes. As estab-
lished by recent gene expression proﬁling studies,44 45 these
patients are characterised by persistent upregulation of genes
associated with T cells, B cells and the monocyte/macrophage
lineage.
Taken together, we identiﬁed a new role of LXRs in inhibiting
experimental ﬁbrosis. Our ﬁndings suggest that activation of
LXRs may reduce both inﬂammation and ﬁbrosis in SSc
patients. LXRs may therefore be promising therapeutic targets
for SSc patients in early stages or with inﬂammatory disease sub-
types. Before translating our ﬁndings into clinical practice,
however, additional studies investigating the role of LXRs in
vascular disease and ﬁbrosis of internal organs are warranted.
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